Have COX‐2 inhibitors influenced the co‐prescription of anti‐ulcer drugs with NSAIDs?
- 3 February 2004
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (3) , 337-343
Abstract
Aims To quantify usage of COX-2 inhibitors compared with nonselective NSAIDs and to determine their impact (including financial) on the co-prescription of antipeptic ulcer (anti-PU) drugs. Methods The Irish General Medical Services prescription database (covering 1.2 million people) was examined for NSAID prescriptions during December 1999-November 2001. NSAID users were excluded during the first 6 months. During the next 12 months (study period) patients on NSAIDs (≥ 3 prescriptions) were identified. The study period and final 6 months provided data on co-prescription of anti-PU drugs. Age, gender, number of concomitant prescriptions, co-prescribing of anti-PU drugs and monthly cost were evaluated for 8 NSAIDs (n= 4 non-selective NSAIDs and n= 4 COX-2 inhibitors) and odds ratios (OR) calculated using logistic regression. Results COX-2 inhibitors were prescribed more frequently in older, female patients and those receiving multiple medications. After adjustment for age, gender and polypharmacy, anti-PU drugs were prescribed more frequently with COX-2 inhibitors (OR = 1.31 (1.23,1.40)). COX-2 inhibitors were up to 10-fold more expensive, median monthly costs (including anti-PU drugs) ranging from €34.61 (COX-2 inhibitors) to €3.26 (nonselective NSAIDs). Conclusions Since COX-2 inhibitors are associated with increased rates of co-prescription of anti-PU drugs and are more expensive than non-selective NSAIDs, these results suggest that the expected cost-savings with COX-2 inhibitors may not be occurring in practice.Keywords
This publication has 14 references indexed in Scilit:
- The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic ArthritisAnnals of Internal Medicine, 2003
- Peptic-ulcer diseaseThe Lancet, 2002
- Pharmacoeconomics of Coxib TherapyJournal of Pain and Symptom Management, 2002
- The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathyRheumatology, 2002
- Drug switching patterns among patients taking non‐steroidal anti‐inflammatory drugs: a retrospective cohort study of a general practitioners database in the United KingdomPharmacoepidemiology and Drug Safety, 2001
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in SwitzerlandPharmacoEconomics, 2001
- Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complicationsThe American Journal of Medicine, 1999
- The cyclooxygenase-2 inhibitors: safety and effectiveness.Annals of Pharmacotherapy, 1999
- Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugsJournal of Clinical Epidemiology, 1992